New fixed bronchodilator combinations of a long-acting β2-agonist and a long-acting anticholinergic

[1]  Yusuke Nakamura,et al.  Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. , 2011, The New England journal of medicine.

[2]  H. Kerstjens,et al.  Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. , 2011, The Journal of allergy and clinical immunology.

[3]  P. Barnes.  Triple inhalers for obstructive airways disease: will they be useful? , 2011, Expert review of respiratory medicine.

[4]  E. Kerwin,et al.  Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. , 2011, Respiratory medicine.

[5]  C. Fogarty,et al.  Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. , 2011, Respiratory medicine.

[6]  D. Tashkin,et al.  Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. , 2011, Pulmonary pharmacology & therapeutics.

[7]  L. Fabbri,et al.  Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients , 2010, COPD.

[8]  J. V. van Noord,et al.  QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease , 2010, Thorax.

[9]  R. Buhl,et al.  Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD , 2010, European Respiratory Journal.

[10]  J. V. van Noord,et al.  Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. , 2010, Respiratory medicine.

[11]  P. Devillier,et al.  Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models , 2010, Journal of Pharmacology and Experimental Therapeutics.

[12]  H. Magnussen,et al.  Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD , 2010, Thorax.

[13]  D. Niewoehner.  Clinical practice. Outpatient management of severe COPD. , 2010, The New England journal of medicine.

[14]  M. Cazzola,et al.  Emerging inhaled bronchodilators: an update , 2009, European Respiratory Journal.

[15]  M. Cazzola.  Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. , 2009, Current opinion in investigational drugs.

[16]  D. Mahler,et al.  Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. , 2009, Respiratory medicine.

[17]  D. Tashkin,et al.  Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.

[18]  C. Vogelmeier,et al.  Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. , 2008, Respiratory medicine.

[19]  M. Littner,et al.  Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. , 2008, Respiratory medicine.

[20]  H. Magnussen,et al.  Onset and Duration of Action of Formoterol and Tiotropium in Patients with Moderate to Severe COPD , 2006, Respiration.

[21]  J. V. van Noord,et al.  Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. , 2006, Chest.

[22]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[23]  M. Cazzola,et al.  The functional impact of adding salmeterol and tiotropium in patients with stable COPD. , 2004, Respiratory medicine.

[24]  M. De Salvo,et al.  In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. , 2001, Chest.

[25]  J. V. van Noord,et al.  The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. , 2009, Respiratory medicine.